Key Takeaways Vinay Prasad is returning as head of the FDA’s Center for Biologics Evaluation and ResearchHe was reportedly ...

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who ...

Vinay Prasad has returned to lead the US regulator’s Center for Biologics Evaluation and Research, resuming responsibility ...

Note that some links may require registration or subscription. DermaRite Industries is recalling certain lots of its over-the ...

The shares of biotech companies fell after news that ousted regulator Vinay Prasad is set to go back to the US Food and Drug Administration.Prasad had previously overruled his own scientific review ...

Today, we discuss lots of government maneuvering that impacts biopharma — starting, of course, with the FDA reinstating Vinay ...

FDA reinstates Vinay Prasad to lead CBER as gene therapy safety concerns spotlight regulatory challenges in biotech manufacturing.

Plus more pharma news from the Pharmalittle newsletter.

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency.

CDC employees across all of the agency’s campuses will be teleworking today, after a gunman shot multiple rounds into four ...

TO APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, ...